Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Official account for ChinaStockResearch.com
Several years experience as an analyst in the hedge fund world. Investment knowledge includes long/short equities, credit, macro, arbitrage, distressed debt, and special situations. Previous research publication experience includes Japanese small cap research distributed to institutional investors. Education credentials include BS in Computer Science, MBA in Finance, and CFA Charter.
Follow on Twitter @ChinaStockRsrch
Follow on StockTwits @ChinaStockResearch
Recent finance graduate. I look for companies with highly-aligned management teams with low valuations on the long side, and poorly-aligned management teams with high valuations, aggressive accounting, and over-leveraged balance sheets on the short side.
Deep value investor in search of companies with clear catalysts for upside. Recent successes of investments in value and activist-focused stocks: Natural Gas Services (NGS), Carbonite (J2 Global tender), Pacer (XPO Logistics), Given Imaging (Covidien), Xyratex (Seagate), Zoltek Companies (Toray Industries), STEC (Western Digital).
Disclaimer: Although well-researched, Shawn is not certified to provide financial advice. He is not held accountable for the actions one takes based on the information he provides. Please do your own research prior to investing.
Gold Stock Trades Editor Jeb Handwerger is a highly sought-after stock analyst syndicated internationally and known throughout the financial industry for his accurate and timely analysis of the equities markets, particularly the metals and mining sector. Subscribe to his FREE Newsletter right now at: http://goldstocktrades.com.
Full-time investor searching for talented operators, clean capital structures & scalable growth. No cigar butts or conventional wisdom. My investment philosophy is similar to how I live my life: acquire a few prized possessions at the right price, minimize clutter and maintain flexibility. Twitter: @indievestments
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
Saj Karsan founded an investment and research firm that is based on the principles of value investing. He has an MBA from the Richard Ivey School of Business, has completed all three CFA exams, and has an engineering degree from McGill University. Visit his blog, Barel Karsan (http://barelkarsan.com/).
I am an individual investor focusing on stocks with high growth potential. I prefer stocks that address new or untapped markets.
I am a recent college graduate from Northern Arizona University. I spend much of my free time looking at investment opportunities and analyzing the underlying businesses. The primary reason I write articles is to showcase my willingness and ability to learn about businesses and provide useful analyses.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
I am a stay-at-home parent that trades stocks . I began trading stocks a number of years ago when I realized that I had a knack for it. I completely immersed myself in the study of stocks and through that process I have learned how to identify investment ideas and profit from it. Been a trader and investor for 10+ years.
Good luck with your investments and I look forward to all of your comments and suggestions.
Wavelength Asset Management seeks to leverage the founders’ extensive expertise investing long and short in the global telecommunications, media and technology (TMT) sectors. Wavelength invests primarily in the equity markets, looking for opportunistic relative valuation and event driven investments. Security selection is driven by rigorous fundamental analysis coupled with a technical overlay, and a focus on identifying critical data-points and potential catalysts.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
EXP is a graduate from The University of Wall Street and serves as the CEO / Chief Stock Strategist at EXPstocktrader.com research firm.
With over 30 years of trading the market, EXP is an experienced investor using a fundamental and technical approach as a market analyst, chartist, visual analyst, as well as, a trader, author, coach, and serial entrepreneur. Extremely dedicated by investing countless hours investigating, analyzing, then writing about unique stock opportunities, as well as, coaching existing followers worldwide. EXP delivers "Real Facts" to Seeking Alpha and Twitter followers on monthly stock selections. Not all of the research found in the EXPstocktrader Monthly Newsletter is openly published online so EXP's members get updates first. Note: Most stocks covered have a unique niche or value proposition.
The Goal is to assist the small to mid-level investor maneuver through the treacherous waters controlled by Hedge Funds and Market Makers. From the EXPstocktrader.com website you will find an offering for a newsletter that gives interested followers several trading ideas and stock lessons on a monthly basis. SA followers only see a very small part of EXP's published research.
This is not an easy business. Wall Street trickery is at an "All Time High" these days; brutally fierce and rampant against small retail investors. Trading is psychological in nature, meaning that the market's psychological warfare can be extremely debilitating. EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities and then manage to act on them.
EXP resides in the USA, and is thankful to followers worldwide.
You can also follow EXPstocktrader on:
Twitter --- @EXPstocktrader
Website --- http://www.EXPstocktrader.com
Email --- firstname.lastname@example.org
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some compensation is paid by SA if the article gets picked for circulation, that's it. Prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader.com and SA are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
Ashraf Eassa is a technology specialist with The Motley Fool. He writes mostly about technology stocks, but is especially interested in anything related to chips -- the semiconductor kind, that is.
I have been a professional writer for over 20 years. I also have enjoyed searching micro and nano cap companies looking for hidden gems. Having grown up around stock brokers and commodities traders I have seen the business from both sides. I have been an investor in the market for most of my life.
I have been analyzing and trading stocks for over 10 years. I have primarily studied and followed value investors like Warren Buffet. However, I also believe that technical analysis can play a role in analyzing a stock before making an investment. I have found that solid financial analysis, combined with the ability to understand current market psychology is key to investment success.
I also find the best trading spot is far away from Wall Street, my favorite place is a sunny beach in Mexico.
I am planning to form a small private equity company which will focus on activist investing and possibly buyouts of smaller capitalization companies.
Mr. Axler is Founding Partner of Spruce Point Capital Management, a long/short hedge fund. Mr. Axler is also the co-founder of Prescience Point Research Group. Mr. Axler is an activist short-seller, forensic financial researcher, and has exposed over $1.0 billion of alleged listed frauds on Nasdaq and the NYSE. Prior to founding his company in 2009, Mr. Axler spent eight years as an investment banker with Credit Suisse and Barclays Capital where he structured and executed billions of dollars of financing, derivative risk management, and M&A deals for leading Fortune 500 clients. Prior to starting Spruce Point, Mr. Axler was an Associate Director at Barclays Capital in the Diversified Industrials Group. Mr. Axler started his career with Credit Suisse in 2000, where he held roles with the Financial Strategy, Corporate Risk Management, and M&A groups.
Mr. Axler is a contributing writer to Seeking Alpha, and was profiled in the book "The Happiness Advantage: The Seven Principles of Positive Psychology That Fuel Success and Performance at Work." Mr. Axler's short research has been profiled by the National Bureau of Economic Research (NBER) in an analysis entitled "How Constraining Are Limits to Arbitrage? Evidence from a Recent Financial Innovation," and shown to produce superior investment returns. In addition, according to a research study from Sumzero analyzing 12,000 analysts recommendations since 2009, Mr. Axler is the top ranking short-seller.
Mr. Axler graduated from Yale University with a masters degree in Statistics, and received both a Bachelor of Arts degree in Statistics and a Bachelor of Science in Marketing and Business Administration from Rutgers College, where he graduated with Summa Cum Laude and Phi Beta Kappa honors.
Fundamental, research-driven fund specializing in ADR, small-cap and distressed companies. Focused on intrinsic value in quality, growing companies along with specific catalysts that can cause share prices to recover.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
I graduated from the University of Toronto with a BComm and am now working on developing a partnering business to help get the word out on disruptive investments. I want my research to provide timely and conclusive investment ideas that intend to deliver attractive yields to investors.
Keep updated with me on Twitter:
I enjoy following and capitalizing on investing opportunities primarily in the tech and healthcare industry. Most of my free time is spent conducting research on small-to-mid cap equities using a combination of fundamental data analysis and technical studies to come to conclusive results. I manage some money that I invest according to the above technique to ripen my exposure to the financial world.
Previously, I spent some time working for a major commercial construction company where I was responsible for running the back office, occasionally overlooking data and logistics. Most of my time was spent in a financial controller capacity.
I write because I believe in sharing my findings and opinions with those interested so they may come to their own conclusions and in turn spark an intelligent and beneficial discussion.
Interested in connecting? Shoot me a message
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.